Valbiotis (ENXTPA:ALVAL) - Share price, News & Analysis

ALVAL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	6/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

ALVAL Stock Overview

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases.

Rewards

Trading at 96.5% below our estimate of its fair value

Earnings are forecast to grow 100.72% per year

Risk Analysis

Makes less than USD$1m in revenue (€298K)

Does not have a meaningful market cap (€60M)

Valbiotis Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Valbiotis
Historical stock prices
Current Share Price	€6.16
52 Week High	€7.45
52 Week Low	€4.01
Beta	0.65
1 Month Change	7.32%
3 Month Change	-4.94%
1 Year Change	-12.00%
3 Year Change	70.64%
5 Year Change	-38.65%
Change since IPO	-38.40%

Recent News & Updates

May 10

Is Valbiotis (EPA:ALVAL) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

	ALVAL	FR Biotechs	FR Market
7D	1.7%	22.6%	0.9%
1Y	-12.0%	-39.0%	-14.0%

Return vs Industry: ALVAL exceeded the French Biotechs industry which returned -39% over the past year.

Return vs Market: ALVAL exceeded the French Market which returned -14% over the past year.

Price Volatility

Is ALVAL's price volatile compared to industry and market?
ALVAL volatility
ALVAL Average Weekly Movement	6.3%
Biotechs Industry Average Movement	6.8%
Market Average Movement	5.0%
10% most volatile stocks in FR Market	9.1%
10% least volatile stocks in FR Market	2.9%

Stable Share Price: ALVAL is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ALVAL's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	41	Sébastien Peltier	https://www.valbiotis.com

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease.

Valbiotis Fundamentals Summary

How do Valbiotis's earnings and revenue compare to its market cap?
ALVAL fundamental statistics
Market Cap	€59.87m
Earnings (TTM)	-€8.68m
Revenue (TTM)	€298.00k

201.0x

P/S Ratio

-6.9x

P/E Ratio

Is ALVAL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALVAL income statement (TTM)
Revenue	€298.00k
Cost of Revenue	€0
Gross Profit	€298.00k
Other Expenses	€8.98m
Earnings	-€8.68m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 30, 2022

Earnings per share (EPS)	-0.89
Gross Margin	100.00%
Net Profit Margin	-2,913.09%
Debt/Equity Ratio	39.4%

How did ALVAL perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is ALVAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALVAL?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ALVAL. This is calculated by dividing ALVAL's market cap by their current preferred multiple.
What is ALVAL's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	€59.87m

ALVAL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	153.2x
Enterprise Value/EBITDA	-5.6x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ALVAL's PB Ratio compare to its peers?

ALVAL PB Ratio vs Peers

The above table shows the PB ratio for ALVAL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	15.4x

Price-To-Book vs Peers: ALVAL is good value based on its Price-To-Book Ratio (4.2x) compared to the peer average (15.4x).

Price to Earnings Ratio vs Industry

How does ALVAL's PE Ratio compare vs other companies in the French Biotechs Industry?

Price-To-Book vs Industry: ALVAL is expensive based on its Price-To-Book Ratio (4.2x) compared to the French Biotechs industry average (2.6x)

Price to Book Ratio vs Fair Ratio

What is ALVAL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALVAL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALVAL's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ALVAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALVAL (€6.16) is trading below our estimate of fair value (€177.83)

Significantly Below Fair Value: ALVAL is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALVAL's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Valbiotis forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

6/6

Future Growth Score 6/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

100.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALVAL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: ALVAL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALVAL is expected to become profitable in the next 3 years.

Revenue vs Market: ALVAL's revenue (70.3% per year) is forecast to grow faster than the French market (5.9% per year).

High Growth Revenue: ALVAL's revenue (70.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ALVAL's Return on Equity is forecast to be very high in 3 years time (83.2%).

Discover growth companies

Past Performance

How has Valbiotis performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-25.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALVAL is currently unprofitable.

Growing Profit Margin: ALVAL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ALVAL is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.

Accelerating Growth: Unable to compare ALVAL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALVAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).

Return on Equity

High ROE: ALVAL has a negative Return on Equity (-60.73%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Valbiotis's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALVAL's short term assets (€25.2M) exceed its short term liabilities (€7.9M).

Long Term Liabilities: ALVAL's short term assets (€25.2M) exceed its long term liabilities (€6.3M).

Debt to Equity History and Analysis

Debt Level: ALVAL has more cash than its total debt.

Reducing Debt: ALVAL's debt to equity ratio has reduced from 162.2% to 39.4% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALVAL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALVAL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies

Dividend

What is Valbiotis's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALVAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALVAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALVAL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALVAL's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALVAL has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure

CEO

Sébastien Peltier (43 yo)

no data

Tenure

Mr. Sébastien Peltier, Ph D., HDR serves as the Chief Executive Officer and Chairman of Valbiotis SA and is Co-Founder of Valbiotis. Mr. Peltier joined Laboratoire Lescuyer in 2007 and served as its in cha...

Leadership Team

Experienced Management: ALVAL's management team is considered experienced (3.3 years average tenure).

Board Members

Experienced Board: ALVAL's board of directors are considered experienced (3.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/24 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31